ERBB2 and neoplasm: Tumor uptake of [64Cu]Cu-NOTA-trastuzumab Fab-PEG24-EGF bsRICs was 1.7-fold higher in SK-OV-3 tumors homogeneously expressing HER2 (8.2 ± 1.7% ID/g) than in tumors with heterogeneous HER2 and EGFR expression but this difference was not significant (4.8 ± 0.6% ID/g; p > 0.05; Table 1).